You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The decade-long project will no longer enroll participants, but research using the collected data will continue.
The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The Cancer Journal documented 25 cases where inappropriate tests were ordered, variants were interpreted incorrectly, and wrong results were reported to patients.
While the FDA has expressed concerns about PGx testing, CEO Erik Hennings said the company has taken measures to limit the risk of consumer harm.
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
In a pilot study, EMD Serono will have the genomes of lung cancer patients sequenced for research but participants will also gain access to their genomic data.
Several genetic test providers thought Helix would give them a national sales channel for their genomics apps, but this didn't materialize.
A company executive confirmed that Helix has laid off an undisclosed number of employees and is closing its Denver and San Francisco offices.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.